Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.07−0.32 (-0.93%)
Close on Nov 18, 2026Market cap $2.25BP/E 6.3Yield –
Lakefront Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was €295.04M. The highest annual figure on record is €368.75M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €295.04M | – |
| FY2024 | Dec 31, 2024 | -€188.34M | – |
| FY2023 | Dec 31, 2023 | -€88.26M | – |
| FY2022 | Dec 31, 2022 | -€131.06M | – |
| FY2021 | Dec 31, 2021 | -€171.57M | – |
| FY2020 | Dec 31, 2020 | -€178.63M | -148.4% |
| FY2019 | Dec 31, 2019 | €368.75M | – |
| FY2018 | Dec 31, 2018 | -€47.08M | – |
| FY2017 | Dec 31, 2017 | -€89.80M | – |
| FY2016 | Dec 31, 2016 | -€11.49M | – |
| FY2015 | Dec 31, 2015 | -€89.44M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2021 | Jun 30, 2021 | -€46.75M | – |
| Q2 FY2020 | Jun 30, 2020 | -€88.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -€44.37M | – |
| Q2 FY2018 | Jun 30, 2018 | -€33.75M | – |
| Q2 FY2017 | Jun 30, 2017 | -€21.68M | – |
See a number that looks wrong?